Published in J Virol on July 11, 2012
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest (2013) 1.44
Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat Commun (2014) 1.04
Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse. Front Neuroanat (2014) 0.96
Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem (2013) 0.96
Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus. Biochemistry (2013) 0.93
Structural insights into adeno-associated virus serotype 5. J Virol (2013) 0.92
An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum Gene Ther (2013) 0.88
Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. J Virol (2013) 0.87
Systemic delivery of shRNA by AAV9 provides highly efficient knockdown of ubiquitously expressed GFP in mouse heart, but not liver. PLoS One (2013) 0.87
Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats. Gene Ther (2014) 0.85
Fetal Brain-directed AAV Gene Therapy Results in Rapid, Robust, and Persistent Transduction of Mouse Choroid Plexus Epithelia. Mol Ther Nucleic Acids (2013) 0.83
C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J Virol (2013) 0.82
CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. Mol Ther Nucleic Acids (2016) 0.79
Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus. J Struct Biol (2013) 0.79
Systemic delivery of adeno-associated viral vectors. Curr Opin Virol (2016) 0.78
Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. J Biol Chem (2014) 0.78
Impact of age and vector construct on striatal and nigral transgene expression. Mol Ther Methods Clin Dev (2016) 0.75
rAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study. Gene Ther (2014) 0.75
Unique glycan signatures regulate adeno-associated virus tropism in the developing brain. J Virol (2015) 0.75
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther (2008) 5.83
Adenovirus serotype 5 hexon mediates liver gene transfer. Cell (2008) 5.00
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 4.67
Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther (2006) 4.64
Production and characterization of adeno-associated viral vectors. Nat Protoc (2006) 4.11
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol (2003) 3.25
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci U S A (2008) 3.00
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther (2011) 2.20
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol (2009) 2.07
Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther (2011) 1.86
Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem (2011) 1.73
Scavenger functions of the liver endothelial cell. Biochem J (1990) 1.59
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest (2011) 1.58
Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther (2010) 1.56
Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther (2012) 1.44
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol (2010) 1.42
Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther (2009) 1.42
Glycans as receptors for influenza pathogenesis. Glycoconj J (2010) 1.38
AAV capsid structure and cell interactions. Methods Mol Biol (2011) 1.36
Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex. Virology (2009) 1.23
Viruses and sialic acids: rules of engagement. Curr Opin Struct Biol (2011) 1.21
Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog (2011) 1.12
Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution. Structure (2012) 1.10
Scavenger endothelial cells of vertebrates: a nonperipheral leukocyte system for high-capacity elimination of waste macromolecules. Proc Natl Acad Sci U S A (2002) 1.06
Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology (2011) 1.05
Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol (2012) 1.03
A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol Ther (2011) 1.00
Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology (2011) 0.99
System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents: Evidence for two modes of rapid evolution. J Biol Chem (2006) 0.99
Adenovirus de-targeting from the liver. Curr Opin Mol Ther (2009) 0.83
Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry (2007) 4.71
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
Preference for immediate over delayed rewards is associated with magnitude of ventral striatal activity. J Neurosci (2006) 3.10
Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatry (2008) 3.01
Genetic variation in human NPY expression affects stress response and emotion. Nature (2008) 2.65
Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol (2006) 2.63
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Perigenual anterior cingulate morphology covaries with perceived social standing. Soc Cogn Affect Neurosci (2007) 1.98
Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther (2011) 1.86
Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther (2007) 1.85
Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem (2011) 1.73
Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A (2009) 1.53
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol (2007) 1.52
Temporal stability of individual differences in amygdala reactivity. Am J Psychiatry (2007) 1.47
Diagnostic utility of plasma procalcitonin for nosocomial pneumonia in the intensive care unit setting. Respir Care (2011) 1.45
Bocavirus episome in infected human tissue contains non-identical termini. PLoS One (2011) 1.29
Recognition of a complex substrate by the KsgA/Dim1 family of enzymes has been conserved throughout evolution. RNA (2006) 1.24
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Long-chain omega-3 fatty acid intake is associated positively with corticolimbic gray matter volume in healthy adults. Neurosci Lett (2007) 1.20
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J Virol (2012) 1.04
Surface loop dynamics in adeno-associated virus capsid assembly. J Virol (2008) 1.04
Human choline transporter gene variation is associated with corticolimbic reactivity and autonomic-cholinergic function. Biol Psychiatry (2006) 1.03
Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol (2012) 0.99
Colour pattern specification in the Mocker swallowtail Papilio dardanus: the transcription factor invected is a candidate for the mimicry locus H. Proc Biol Sci (2008) 0.99
Optical Control of CRISPR/Cas9 Gene Editing. J Am Chem Soc (2015) 0.98
Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Curr Protoc Mol Biol (2007) 0.97
Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J Virol (2009) 0.97
Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr Protoc Neurosci (2011) 0.97
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther (2015) 0.97
Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem (2013) 0.96
NIM811 prevents mitochondrial dysfunction, attenuates liver injury, and stimulates liver regeneration after massive hepatectomy. Transplantation (2011) 0.94
Evidenced-based factors in readmission of patients with heart failure. J Nurs Care Qual (2006) 0.93
Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. J Virol (2013) 0.87
Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol (2012) 0.87
Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection. ACS Chem Biol (2012) 0.86
VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Angiogenesis (2010) 0.85
Production of recombinant adeno-associated viral vectors. Curr Protoc Hum Genet (2007) 0.83
AAV does the shuffle. Nat Biotechnol (2006) 0.83
Transient receptor potential A1 activation prolongs isoflurane induction latency and impairs respiratory function in mice. Anesthesiology (2015) 0.83
Serotonin. Am J Psychiatry (2006) 0.83
Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration. Curr Protoc Neurosci (2006) 0.82
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Hum Gene Ther (2014) 0.82
Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opin Biol Ther (2015) 0.81
Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide. Bioconjug Chem (2011) 0.80
Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Mol Pain (2014) 0.80
Systemic gene transfer to skeletal muscle using reengineered AAV vectors. Methods Mol Biol (2011) 0.77
Probing the Link among Genomic Cargo, Contact Mechanics, and Nanoindentation in Recombinant Adeno-Associated Virus 2. J Phys Chem B (2017) 0.76
Cytosolic delivery of macromolecules: I. Synthesis and characterization of pH-sensitive acyloxyalkylimidazoles. Biochim Biophys Acta (2003) 0.76
Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids. PLoS One (2012) 0.76
Glycated AAV vectors: chemical redirection of viral tissue tropism. Bioconjug Chem (2011) 0.76
Hemophilic synovitis: factor VII and the potential role of extravascular factor VIIa. Thromb Res (2010) 0.75
A cautionary tale: threatened compartment syndrome following electromyography in an anticoagulated patient. Muscle Nerve (2012) 0.75
Effects on carbon and nitrogen emissions due to swine manure removal for biofuel production. J Environ Qual (2012) 0.75